Phase 3 Readout~month

Phase 3 Topline: An Open-Label, Multicenter, Randomized, Non-Inferiority Pharmacokinetic and Safety/Tolerability Stud

Indication
Alpha 1 Antitrypsin Deficiency

Other upcoming events for GRFS

Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose R
Phase 3 ReadoutPhase 3 Topline: An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamun
Phase 3 ReadoutPhase 3 Topline: An Open-label, Multi-Center, Single-arm Prospective Clinical Trial to Evaluate Efficacy, Safety, and
Phase 3 ReadoutPhase 3 Topline: An Open-Label, Multicenter Study to Evaluate the Long-term Safety of Weekly Intravenous Alpha1-Prote

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: An Open-Label, Multicenter, Randomized, Non-Inferiority Pharmacokinetic and Safety/Tolerability Stud — GRFS Phase 3 Readout | BioSniper